FAPI Compared with FDG PET/CT for Diagnosis of Primary and Metastatic Lung Cancer DOI
Yuchun Wei,

Li Ma,

Pei Li

et al.

Radiology, Journal Year: 2023, Volume and Issue: 308(2)

Published: Aug. 1, 2023

Background The radiotracer fluorine 18 (18F)–labeled fibroblast activation protein inhibitor (FAPI) has shown promise for visualizing several types of cancer, but the accuracy 18F-FAPI compared with 18F-fluorodeoxyglucose (FDG) detection lung cancer remains uncertain. Purpose To evaluate effectiveness 18F-FAPI–based PET/CT imaging diagnosis primary and metastatic lesions as 18F-FDG PET/CT. Materials Methods In this secondary analysis a prospective trial, consecutively recruited patients from single center pathologically confirmed were prospectively enrolled December 2020 to April 2022 underwent paired examinations at intervals more than 20 hours within 7 days each other. Histopathologic clinical follow-up results used reference standards final diagnoses. uptake using McNemar test or Student t test. Diagnostic was between two techniques by χ2 Results Sixty-eight participants (median age, 63 years [IQR, 58–68 years; range, 42–79 years]; 46 male [68%]) evaluated. Compared mean tumor-to-background ratio (TBR) FDG uptake, TBR FAPI lower in tumors (25.3 ± 14.0 [SD] vs 32.1 21.1; P < .001) higher lymph nodes (7.5 6.6 5.9 8.6; bone metastases (8.6 5.4 4.3 2.3; .001). For diagnostic total 548 68 participants, PET/CT, demonstrated sensitivity (99% [392 397 lesions] 87% [346 397]; .001), specificity (93% [141 151 79% [120 151]; = .004), (97% [533 85% [466 548]; negative predictive value 146 70% 171 lesions]; there no evidence difference positive (98% 402 92% 377 .57). Conclusion may be superior detecting cancer. © RSNA, 2023 Supplemental material is available article. See also editorial Zukotynski Gerbaudo issue.

Language: Английский

FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease DOI
Yuriko Mori, Katharina Dendl, Jens Cardinale

et al.

Radiology, Journal Year: 2023, Volume and Issue: 306(2)

Published: Jan. 3, 2023

Gallium 68 (68Ga)–labeled fibroblast activation protein (FAP) inhibitor (FAPI) PET is based on the molecular targeting of FAP, which known to be highly expressed in major cell population tumor stroma, termed cancer-associated fibroblasts. Among many FAP-targeted radiopharmaceuticals developed so far, 68Ga-FAPI exhibits rapid tracer accumulation target lesions and low background signal, results excellent imaging features. FAPI can integrated clinical workflow enables detection small primary or metastatic lesions, especially brain, liver, pancreas, gastrointestinal tract due these organs. Moreover, DOTA (1,4,7,10-tetraazacylclododecane-1,4,7,10-tetrayl tetraacetic acid) chelator structure allows coupling molecules with therapeutic emitters such as yttrium 90 for theranostic applications. This review provides an overview state art FAP imaging, summarizes current knowledge relevant cancer biology, highlights latest findings use other tracers. Published under a CC BY 4.0 license

Language: Английский

Citations

185
State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis DOI
Martina Sollini, Margarita Kirienko, Fabrizia Gelardi

et al.

European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2021, Volume and Issue: 48(13), P. 4396 - 4414

Published: June 25, 2021

Language: Английский

Citations

129
Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review DOI Creative Commons
Liang Zhao, Jianhao Chen, Yizhen Pang

et al.

Theranostics, Journal Year: 2022, Volume and Issue: 12(4), P. 1557 - 1569

Published: Jan. 1, 2022

In recent years, quinoline-based fibroblast activation protein (FAP) inhibitors (FAPI) have shown promising results in the diagnosis of cancer and several other diseases, making them hotspot much productive research. This review summarizes literature for state-of-the-art FAPI-PET imaging compared with fluorodeoxyglucose (FDG)-PET. We also summarize use therapeutic regimen improvement (FAP)-targeted molecule modification strategies, as well preliminary clinical studies regarding FAP-targeted radionuclide therapy. Our qualitative summary to date can inform future research directions, medical guidelines, optimal decision-making.

Language: Английский

Citations

127
Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Evaluation of Advanced Lung Cancer DOI
Lijuan Wang, Ganghua Tang, Kongzhen Hu

et al.

Radiology, Journal Year: 2022, Volume and Issue: 303(1), P. 191 - 199

Published: Jan. 4, 2022

Background Gallium 68 (68Ga)–labeled fibroblast-activation protein inhibitor (FAPI) has recently been introduced as a promising tumor imaging agent. Purpose To compare 68Ga-FAPI PET/CT with fluorine 18 (18F)–labeled fluorodeoxyglucose (FDG) in evaluating lung cancer. Materials and Methods In this prospective study conducted from September 2020 to February 2021, images participants cancer who underwent both 18F-FDG examinations were analyzed. The tracer uptakes, quantified by maximum standardized uptake value (SUVmax) target-to-background ratio (TBR), compared for paired positive lesions between modalities using the t test or Wilcoxon signed-rank test. Results Thirty-four (median age, 64 years [interquartile range: 46–80 years]; 20 men) evaluated. From visual evaluation, showed similar performance delineation of primary tumors detection suspected metastases lungs, liver, adrenal glands. metabolic volume recurrent no difference (mean: 11.6 vs 10.8, respectively; P = .68). However, PET/CT, depicted more lymph nodes (356 320), brain (23 10), bone (109 91), pleura (66 35). semiquantitative SUVmax TBR tumors, nodes, lesions, pleural at all higher than those (all < .01). Although not different (mean SUVmax: 9.0 7.4, .32), was 314.4 1.0, .02). Conclusion 68–labeled may outperform 18–labeled staging cancer, particularly metastasis brain, bone, pleura. © RSNA, 2022 Online supplemental material is available article. See also editorial Jacobson Van den Abbeele issue.

Language: Английский

Citations

118
68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT DOI Open Access
Chunxia Qin, Fuqiang Shao, Yongkang Gai

et al.

Journal of Nuclear Medicine, Journal Year: 2021, Volume and Issue: 63(1), P. 81 - 88

Published: April 16, 2021

We sought to evaluate the performance of 68Ga-DOTA-FAPI-04 (68Ga-FAPI) PET/MR for diagnosis primary tumor and metastatic lesions in patients with gastric carcinomas compare results those 18F-FDG PET/CT. Methods: Twenty histologically proven were recruited, each patient underwent both PET/CT 68Ga-FAPI PET/MR. A visual scoring system was established detectability tumors metastases different organs or regions (the peritoneum, abdominal lymph nodes, supradiaphragmatic liver, ovary, bone, other tissues). The original SUVmax normalized (calculated by dividing a lesion’s SUVmean descending aorta) selected on 68Ga-FAPI measured. Original/normalized SUVmax-FAPI SUVmax-FDG compared patient-based (including single lesion highest activity uptake organ/region) lesion-based all [≤5] 5 [>5]) analyses, respectively. Results: 20 recruited (median age: 56.0 y; range: 29–70 y) included 9 men 11 women, 14 initial staging 6 recurrence detection. PET superior detection (100.00% [14/14] vs. 71.43% [10/14]; P = 0.034), former had higher tracer levels (P < 0.05). evaluation except nodes ovaries. Additionally, multiple sequences MR images beneficial interpretation hepatic 3 patients, uterine rectal 1 patient, ovarian 7 osseous 2 patients. Conclusion:68Ga-FAPI outperformed visualizing most cancer might be promising method, potential replacing

Language: Английский

Citations

116
FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis? DOI Open Access
Katharina Dendl, Stefan A. Koerber, Clemens Kratochwil

et al.

Cancers, Journal Year: 2021, Volume and Issue: 13(19), P. 4946 - 4946

Published: Sept. 30, 2021

A fibroblast activation protein (FAP) is an atypical type II transmembrane serine protease with both endopeptidase and post-proline dipeptidyl peptidase activity. FAP overexpressed in cancer-associated fibroblasts (CAFs), which are found most epithelial tumors. CAFs have been implicated promoting tumor cell invasion, angiogenesis growth their presence correlates a poor prognosis. However, can generally be during the remodeling of extracellular matrix therefore detected wound healing benign diseases. For instance, chronic inflammation, arthritis, fibrosis ischemic heart tissue after myocardial infarction FAP-positive Therefore, quinoline-based inhibitors (FAPIs) bind high affinity not only to tumors but also variety pathologic processes. When these radiolabeled positron emitting radioisotopes, they provide new diagnostic prognostic tools as well insights into role microenvironment disease. In this respect, deliver additional information beyond what afforded by conventional FDG PET scans that typically report on glucose uptake. Thus, ligands considered highly promising novel tracers offer theranostic potential

Language: Английский

Citations

113
Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond DOI
Mengting Li, Muhsin H. Younis, Yongxue Zhang

et al.

European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2022, Volume and Issue: 49(8), P. 2844 - 2868

Published: Jan. 31, 2022

Language: Английский

Citations

81
FAPI PET/CT Imaging—An Updated Review DOI Creative Commons

Kunal Ramesh Chandekar,

Arun Prashanth,

Sobhan Vinjamuri

et al.

Diagnostics, Journal Year: 2023, Volume and Issue: 13(12), P. 2018 - 2018

Published: June 9, 2023

Despite revolutionizing the field of oncological imaging, Positron Emission Tomography (PET) with [

Language: Английский

Citations

53
FAPI-avid nonmalignant PET/CT findings: An expedited systematic review DOI Creative Commons
Morten Bentestuen,

Noor Al-Obaydi,

Helle D. Zacho

et al.

Seminars in Nuclear Medicine, Journal Year: 2023, Volume and Issue: 53(5), P. 694 - 705

Published: Feb. 20, 2023

Fibroblast activation protein inhibitor (FAPI) is a promising tracer in oncologic positron emission tomography/computed tomography (PET/CT). Numerous studies have demonstrated the superior sensitivity of FAPI PET/CT over fluorodeoxyglucose (FDG) several types cancer. However, cancer specificity uptake remains understudied, and cases false-positive findings been reported. A systematic search PubMed, Embase, Web Science was conducted for published prior to April 2022 reporting nonmalignant findings. We included original peer-reviewed articles humans using tracers radiolabeled with 68Ga or 18F that were English. Papers without data insufficient information excluded. Nonmalignant presented on per-lesion basis grouped according type organ tissue involved. The identified total 1.178 papers, which 108 eligible. Eighty case reports (74%), remaining 28 cohort (26%). 2.372 FAPI-avid reported, most frequent being arteries, e.g., related plaques (n = 1178, 49%). also frequently degenerative traumatic bone joint lesions 147, 6%) arthritis 92, 4%). For organs, diffuse focal often seen inflammation, infection, fibrosis, IgG4-related disease 157, 7%). inflammatory/reactive lymph nodes 121, 5%) tuberculosis 51, 2%) reported could prove be potential pitfalls staging. Periodontitis 76, 3%), hemorrhoids 47, 2%), scarring/wound healing 35, as PET/CT. present review provides an overview date. large number benign clinical entities may show should kept mind when interpreting patients

Language: Английский

Citations

45
circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis DOI Creative Commons
Yan Zhao, Yunlong Jia,

Jiali Wang

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: March 8, 2024

Abstract Background Cancer-associated fibroblasts (CAFs) orchestrate a supportive niche that fuels cancer metastatic development in non-small cell lung (NSCLC). Due to the heterogeneity and plasticity of CAFs, manipulating activated phenotype is promising strategy for therapy. However, underlying mechanisms fibroblast activation switching drive metastasis remain elusive. Methods The clinical implications protein (FAP)-positive CAFs (FAP + CAFs) were evaluated based on tumor specimens from NSCLC patients bioinformatic analysis online databases. CAF-specific circular RNAs (circRNAs) screened by circRNA microarrays primary human matched normal (NFs). Survival analyses performed assess prognostic value circNOX4 samples. biological effects investigated gain- loss-of-function experiments vitro vivo. Fluorescence situ hybridization, luciferase reporter assays, RNA immunoprecipitation, miRNA rescue conducted elucidate activation. Cytokine antibody array, transwell coculture system, enzyme-linked immunosorbent assay (ELISA) investigate downstream effectors promote metastasis. Results FAP significantly enriched samples, their higher abundance was correlated with worse overall survival patients. A novel circRNA, (hsa_circ_0023988), evoked phenotypic transition NFs into promoted migration invasion Clinically, poor prognosis advanced Mechanistically, upregulated sponging miR-329-5p, which led Furthermore, circNOX4/miR-329-5p/FAP axis an inflammatory preferentially inducing interleukin-6 (IL-6) eventually promoting progression. Disruption intercellular circNOX4/IL-6 suppressed growth colonization Conclusions Our study reveals role circRNA-induced highlights targeting circNOX4/FAP/IL-6 intervention

Language: Английский

Citations

20